Navigation Links
Dana-Farber Cancer Institute Chooses MicroStrategy for Clinical Operations and Clinical Research Reporting Applications

MCLEAN, Va., Jan. 21 /PRNewswire-FirstCall/ -- MicroStrategy(R) Incorporated (Nasdaq: MSTR), a leading worldwide provider of business intelligence (BI) software, today announced that Dana-Farber Cancer Institute has selected the MicroStrategy Business Intelligence Platform(TM) for clinical operations and clinical research reporting applications. Dana-Farber Cancer Institute is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States.

Dana-Farber will use MicroStrategy for its clinical operations reporting application, which will be used by clinic managers, nurses, disease program administrators, and schedulers to improve their ability to manage patient flow through clinical areas, reduce wait times, optimize clinical processes like pharmacy dispenses and medical records management, and monitor staffing levels. Clinical research assistants, statisticians, doctors, and clinical researchers will use the MicroStrategy-based clinical research reporting application for insights into data that will help them write research papers and grants, identify patients for clinical studies, and better understand treatment outcomes.

"We selected MicroStrategy because we needed a fully integrated business intelligence platform that was reliable, scalable, and easy to use," said John Orechia, Clinical and Research Reporting Team Leader of Dana-Farber Cancer Institute. "With MicroStrategy's robust reporting and intuitive Web interface, our personnel will have access to the information they need to make essential decisions for our organization and our patients."

"We are proud to support Dana-Farber Cancer Institute and its multiple reporting applications," said MicroStrategy's COO Sanju Bansal. "Organizations across the healthcare industry rely on MicroStrategy to analyze and improve operations, service quality, and resource utilization."

About Dana-Farber Cancer Institute

Dana-Farber Cancer Institute ( is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute.

About MicroStrategy

Founded in 1989, MicroStrategy is a global leader in business intelligence (BI) technology. MicroStrategy provides integrated reporting, analysis, and monitoring software that helps leading organizations worldwide make better business decisions every day. Companies choose MicroStrategy for its advanced technical capabilities, sophisticated analytics, and superior data and user scalability. More information about MicroStrategy (Nasdaq: MSTR) is available at

MicroStrategy and MicroStrategy Business Intelligence Platform are either trademarks or registered trademarks of MicroStrategy Incorporated in the United States and certain other countries. Other product and company names mentioned herein may be the trademarks of their respective owners.

    Wende Cover
    MicroStrategy Incorporated

SOURCE MicroStrategy Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Corey McPherson Nash Develops Case Statement for Dana-Farber Cancer Institute Capital Campaign
2. Dana-Farber Cancer Institute Completes Deployment of MedAptus Infusion Services Module
3. Dana-Farber Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
4. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
5. Survival differences by race most apparent in advanced stages of breast cancer
6. MRI finds breast cancer before it becomes dangerous
7. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
8. Pathway links inflammation, angiogenesis and breast cancer
9. Radiologists encouraged to look beyond cancer for clinically unseen diseases
10. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
11. Immune deficiency linked to a type of eye cancer
Post Your Comments:
(Date:10/13/2015)... Boulder, Colorado (PRWEB) , ... October 13, 2015 ... ... launched the first high-tech foam roller with 11 hours of vibrating power. Tested ... to reduce recovery time and increase athletic performance. , Mark's background in sporting ...
(Date:10/13/2015)... , ... October 13, 2015 , ... The American Institutes ... college campus health staff caring for students who have experienced sexual assault and other ... the White House during the Violence Against Women Act's 21st anniversary. ...
(Date:10/13/2015)... M.A. (PRWEB) , ... October 13, 2015 , ... Sir ... service to the local Boston chapter of Ronald McDonald House Charities® (RMHC®). This ... that has supported Sir Grout of Greater Boston since its inception. , “We believe ...
(Date:10/13/2015)... ... ... "My friend's son suffers from eczema, and he had a horrible habit ... Platteville, Colo. "I came up with this kit as a way to prevent children ... child from rubbing or scratching his or her face. This protects sensitive skin from ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... anesthesia and pain management services, today announced its partnership with WPC Healthcare ... data from disparate systems and organizes the data into an aggregated data repository ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... Oct. 13, 2015 Attracting mid- to large-sized medical ... to growing Baltimore into a major ... by the Maryland Technology Enterprise Institute (Mtech) . ... pieces in place to support innovation hubs and a thriving ... Mtech Baltimore. "This study is important because we believe ...
(Date:10/13/2015)... , Oct. 13, 2015  Graduate students ... care and medical research, will soon have the ... patient care – the drug discovery and development ... ) has collaborated with 10 leaders from academic ... "Making Medicines: The Process of Drug Development."  Lilly ...
(Date:10/13/2015)... SAN FRANCISCO , October 13, 2015 ... expected to reach USD 26.8 billion by 2022, according ... Anesthesia and respiratory devices, owing to their capability to ... expected to witness a substantial growth. --> ... reach USD 26.8 billion by 2022, according to a ...
Breaking Medicine Technology: